Cav1 inhibits benign skin tumor development in a two-stage carcinogenesis model by suppressing epidermal proliferation

American Journal of Translational Research

Volumn 5, Issue 1, 2013, Pages 80-91

  Trimmer, Casey ^a   Capozza, Franco ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cav1; Caveolin; Skin; Skin cancer; Two stage carcinogenesis

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BENIGN SKIN TUMOR; CANCER INHIBITION; CELL ISOLATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; KERATINOCYTE; MOUSE; NICK END LABELING; NONHUMAN; PAPILLOMA; SKIN CARCINOGENESIS; WESTERN BLOTTING;

MUS;

EID: 84872784399     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Yamada E. The fne structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1955; 1: 445-458.
2. Lisanti MP, Scherer PE, Tang Z and Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 1994; 4: 231-235.
3. Razani B, Woodman SE and Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002; 54: 431-467.
4. Li S, Song KS and Lisanti MP. Expression and characterization of recombinant caveolin. Purification by polyhistidine tagging and cholesterol-dependent incorporation into defned lipid membranes. J Biol Chem 1996; 271: 568-573.
5. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276: 38121-38138.
6. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P and Lisanti MP. Cell-type and tissue-specifc expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 1997; 272: 29337-29346.
7. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF and Lisanti MP. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 1996; 271: 2255-2261.
8. Engelman JA, Zhang XL, Galbiati F and Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett 1998; 429: 330-336.
9. Engelman JA, Zhang XL and Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998; 436: 403-410.
10. Zenklusen JC, Thompson JC, Klein-Szanto AJ and Conti CJ. Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res 1995; 55: 1347-1350.
11. Menendez L, Walker D, Matyunina LV, Dickerson EB, Bowen NJ, Polavarapu N, Benigno BB and McDonald JF. Identifcation of candidate methylation-responsive genes in ovarian cancer. Mol Cancer 2007; 6: 10.
12. Syeed N, Hussain F, Husain SA and Siddiqi MA. 5'-CpG island promoter hypermethylation of the CAV-1 gene in breast cancer patients of Kashmir. Asian Pac J Cancer Prev 2012; 13: 371-375.
13. Engelman JA, Zhang XL and Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 1999; 448: 221-230.
14. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T and Hama-guchi M. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001; 61: 2361-2364.
15. Lee H, Park DS, Razani B, Russell RG, Pestell RG and Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002; 161: 1357-1369.
16. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG and Lisanti MP. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 2003; 14: 1027-1042.
17. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F and Lisanti MP. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 2003; 162: 2029-2039.
18. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD and Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-3885.
19. Yang G, Truong LD, Wheeler TM and Thompson TC. Caveolin-1 expression in clinically confned human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59: 5719-5723.
20. Langlois S, Cowan KN, Shao Q, Cowan BJ and Laird DW. The tumor-suppressive function of Connexin43 in keratinocytes is mediated in part via interaction with caveolin-1. Cancer Res 2011; 70: 4222-4232.
21. Miller DL and Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30: 774-778.
22. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS and Roenigk RK. Trends in the populationbased incidence of squamous cell carcinoma of the skin frst diagnosed between 1984 and 1992. Arch Dermatol 1997; 133: 735-740.
23. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB and Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2011; 146: 283-287.
24. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-1667.
25. Abel EL, Angel JM, Kiguchi K and DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications. Nat Protoc 2009; 4: 1350-1362.
26. Alam M and Ratner D. Cutaneous squamouscell carcinoma. N Engl J Med 2001; 344: 975-983.
27. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML and Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol 2005; 23: 759-765.
28. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, Gould C, Gemmen E and Dall T. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490-500.
29. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer 2004; 4: 23-35.
30. Roelandt T, Giddelo C, Heughebaert C, Denecker G, Hupe M, Crumrine D, Kusuma A, Haftek M, Roseeuw D, Declercq W, Feingold KR, Elias PM and Hachem JP. The "caveolae brake hypothesis" and the epidermal barrier. J Invest Dermatol 2009; 129: 927-936.
31. Campbell L, Laidler P, Watson RE, Kirby B, Griffths CE and Gumbleton M. Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. Br J Dermatol 2002; 147: 701-709.
32. Lichti U, Anders J and Yuspa SH. Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodefcient mice. Nat Protoc 2008; 3: 799-810.
33. Pirrone A, Hager B and Fleckman P. Primary mouse keratinocyte culture. Methods Mol Biol 2005; 289: 3-14.
34. Capozza F, Combs TP, Cohen AW, Cho YR, Park SY, Schubert W, Williams TM, Brasaemle DL, Jelicks LA, Scherer PE, Kim JK and Lisanti MP. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am J Physiol Cell Physiol 2005; 288: C1317-1331.
35. Capozza F, Cohen AW, Cheung MW, Sotgia F, Schubert W, Battista M, Lee H, Frank PG and Lisanti MP. Muscle-specifc interaction of caveolin isoforms: differential complex formation between caveolins in fbroblastic vs. muscle cells. Am J Physiol Cell Physiol 2005; 288: C677-691.
36. Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP and Capozza F. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res 2010; 70: 7489-7499.
37. Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM and Yuspa SH. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinoma in the skin. Carcinogenesis 1993; 14: 2353-2358.
38. Woodworth CD, Michael E, Smith L, Vijayachandra K, Glick A, Hennings H and Yuspa SH. Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte. Carcinogenesis 2004; 25: 1771-1778.
39. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J and DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004; 114: 720-728.
40. Mora R, Bonilha VL, Marmorstein A, Scherer PE, Brown D, Lisanti MP and Rodriguez-Boulan E. Caveolin-2 localizes to the golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1. J Biol Chem 1999; 274: 25708-25717.
41. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C and Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J Biol Chem 1999; 274: 25718-25725.
42. Yamamoto H, Ochiya T, Takeshita F, Toriyama-Baba H, Hirai K, Sasaki H, Sasaki H, Sakamoto H, Yoshida T, Saito I and Terada M. Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res 2002; 62: 1641-1647.
43. Cohen AW, Hnasko R, Schubert W and Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379.
44. Song KS, Li S, Okamoto T, Quilliam LA, Sargia-como M and Lisanti MP. Co-purifcation and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purifcation of caveolae microdomains. J Biol Chem 1996; 271: 9690-9697.
45. Mineo C, James GL, Smart EJ and Anderson RG. Localization of epidermal growth factorstimulated Ras/Raf-1 interaction to caveolae membrane. J Biol Chem 1996; 271: 11930-11935.
46. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS and Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998; 428: 205-211.
47. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG and Lisanti MP. Targeted downregulation of caveolin-1 is suffcient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17: 6633-6648.
48. Lajoie P, Partridge EA, Guay G, Goetz JG, Pawl-ing J, Lagana A, Joshi B, Dennis JW and Nabi IR. Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol 2007; 179: 341-356.
49. Mineo C, Gill GN and Anderson RG. Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem 1999; 274: 30636-30643.
50. Prior IA, Harding A, Yan J, Sluimer J, Parton RG and Hancock JF. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol 2001; 3: 368-375.
51. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB and Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fbroblasts. Am J Physiol Cell Physiol 2003; 284: C457-474.
52. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG and Lisanti MP. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol 2006; 169: 1784-1801.
53. Cargnello M and Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.
54. Meloche S and Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1to S-phase transition. Oncogene 2007; 26: 3227-3239.
55. Campbell L and Gumbleton M. Aberrant caveolin-1 expression in psoriasis: a signalling hypothesis. IUBMB Life 2000; 50: 361-364.